TIGIT as an emerging immune checkpoint

LAG-3 and TIGIT protein expressions in cutaneous melanoma and their relationship with PD-1 tumor-infiltrating lymphocytes

(2019) Woo Jin Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy

(2019) Beatriz Sanchez-Correa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer

(2019) Shaun M. O'Brien et al.   Cancer Immunology Research

Expression of immune checkpoint receptors Indoleamine 2,3‐dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma

(2019) Gustav Stålhammar et al.   Cancer Medicine

Clinical significance of CD8+ T cell immunoreceptor with Ig and ITIM domains+ in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy

(2019) Weiwei Tang et al.   OncoImmunology

Treatment of murine lupus with TIGIT-Ig

(2019) Shuowu Liu et al.   CLINICAL IMMUNOLOGY

Advances in cancer immunotherapy 2019 – latest trends

(2019) Stephan Kruger et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function

(2019) Clara Degos et al.   Frontiers in Immunology

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

(2019) Mathieu Grapin et al.   Journal for ImmunoTherapy of Cancer

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy

(2019) Beatriz Sanchez-Correa et al.   Cancers

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

(2019) Shiran Hoogi et al.   Journal for ImmunoTherapy of Cancer

TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma

(2018) Camille Guillerey et al.   BLOOD

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity

(2018) Karen O. Dixon et al.   JOURNAL OF IMMUNOLOGY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

(2018) Alice L. Hung et al.   OncoImmunology

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis

(2018) Heidi Harjunpää et al.   OncoImmunology

Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade

(2018) Simone A. Minnie et al.   BLOOD

TIGIT: a novel immunotherapy target moving from bench to bedside

(2018) Benjamin L. Solomon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens

(2018) Daniel M. Altmann   IMMUNOLOGY

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

(2017) William C. Dougall et al.   IMMUNOLOGICAL REVIEWS

Contribution of inhibitory receptor TIGIT to NK cell education

(2017) Yuke He et al.   JOURNAL OF AUTOIMMUNITY

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

(2017) Nicholas A. Manieri et al.   TRENDS IN IMMUNOLOGY

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

(2016) Dhifaf Sarhan et al.   CANCER RESEARCH

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

(2016) Y. Kong et al.   CLINICAL CANCER RESEARCH

TIGIT negatively regulates inflammation by altering macrophage phenotype

(2016) Xi Chen et al.   IMMUNOBIOLOGY

Identification of CD112R as a novel checkpoint for human T cells

(2016) Yuwen Zhu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

(2016) Takashi Inozume et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

(2016) S. J. Blake et al.   Cancer Discovery

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

(2016) Glen M. Chew et al.   PLoS Pathogens

Immune checkpoint blockade in hematologic malignancies

(2015) P. Armand   BLOOD

Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework

(2015) Rienk Offringa et al.   CANCER CELL

Human dendritic cell subsets and function in health and disease

(2015) Meredith O’Keeffe et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack

(2015) Chamutal Gur et al.   IMMUNITY

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

(2015) Camille Guillerey et al.   JOURNAL OF CLINICAL INVESTIGATION

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

TIGIT predominantly regulates the immune response via regulatory T cells

(2015) Sema Kurtulus et al.   JOURNAL OF CLINICAL INVESTIGATION

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226

(2015) Christopher A. Fuhrman et al.   JOURNAL OF IMMUNOLOGY

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

(2015) Annie A Wu et al.   OncoImmunology

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma

(2015) Valentina Bevelacqua et al.   Oncotarget

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

(2014) Man Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

(2014) Christopher J Chan et al.   NATURE IMMUNOLOGY

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

(2013) Noa Stanietsky et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers

(2013) Tsutomu Oshima et al.   Molecular Cancer

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

(2012) S Liu et al.   CELL DEATH AND DIFFERENTIATION

Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer

(2012) Christopher J Chan et al.   CURRENT OPINION IN IMMUNOLOGY

The TIGIT/CD226 Axis Regulates Human T Cell Function

(2012) E. Lozano et al.   JOURNAL OF IMMUNOLOGY

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering

(2012) K. F. Stengel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD155 on Human Vascular Endothelial Cells Attenuates the Acquisition of Effector Functions in CD8 T Cells

(2011) Nichole K. Escalante et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

(2011) Steven D. Levin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

(2009) Javier G. Casado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

(2009) Kent S. Boles et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Accelerated tumor growth in mice deficient in DNAM-1 receptor

(2008) Akiko Iguchi-Manaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors

(2008) Susan Gilfillan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY